Compare BVS & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BVS | IVA |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 982.2M | 895.3M |
| IPO Year | 2016 | 2020 |
| Metric | BVS | IVA |
|---|---|---|
| Price | $13.63 | $3.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $14.00 | ★ $16.20 |
| AVG Volume (30 Days) | 460.2K | ★ 1.3M |
| Earning Date | 05-06-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 163.46 | N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $568,087,000.00 | N/A |
| Revenue This Year | $7.52 | N/A |
| Revenue Next Year | $7.06 | $751.20 |
| P/E Ratio | $26.25 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.26 | $3.35 |
| 52 Week High | $15.89 | $7.98 |
| Indicator | BVS | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 50.84 | 24.92 |
| Support Level | $13.44 | $3.35 |
| Resistance Level | $14.71 | $4.78 |
| Average True Range (ATR) | 0.51 | 0.25 |
| MACD | -0.08 | -0.10 |
| Stochastic Oscillator | 51.85 | 3.09 |
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.